106 filings
Page 4 of 6
8-K
vtrcwxeg5cs5gnr
10 Nov 22
Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update
7:12am
8-K
33hpgkh0sgbu6nsf b5
20 Oct 22
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
7:12am
EFFECT
pdrlwph3
26 Aug 22
Notice of effectiveness
12:15am
CORRESP
ciiwbx rp583ipu3o
23 Aug 22
Correspondence with SEC
12:00am
UPLOAD
nr43 ww2k
22 Aug 22
Letter from SEC
12:00am
S-3
c99mv90b fe7qgwn9
15 Aug 22
Shelf registration
5:06pm
8-K
i6dxkh0z6kd p4w8h1
15 Aug 22
Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update
7:13am
8-K
ezi13fltvah9mgg
30 Jun 22
Other Events
4:54pm
8-K
es7a6evm418hk0xvizsh
13 Jun 22
Submission of Matters to a Vote of Security Holders
5:09pm
8-K
6ocezec0kes303ym4im8
17 May 22
Talaris Therapeutics Announces Changes to Board of Directors
8:29am
8-K
3bb6 r0fejkmk
12 May 22
Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update
4:07pm
DEFA14A
28th5d0vhrxcz1bcslti
29 Apr 22
Additional proxy soliciting materials
4:27pm
DEF 14A
9kym2 nx3jd707pblnd
29 Apr 22
Definitive proxy
4:24pm
S-8
6cx2 mpgi3i
17 Mar 22
Registration of securities for employees
4:41pm
10-K
us34kl6napv fy
17 Mar 22
Annual report
4:31pm
8-K
p6hvoef te75
17 Mar 22
Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results and Provides Business Update
4:13pm